Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02880319 · ClinicalTrials.gov registry record · Phase 2
Evaluating Stereotactic Body Radiation Therapy for Oligometastatic Disease of the Bone
A Phase 2 study of Bone Cancer, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT02880319 is a Phase 2 study of Bone Cancer that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 150 participants, below the 686-participant average among 3 other Bone Cancer trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02880319, a Phase 2 study of Bone Cancer, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is studying a form of radiation therapy called stereotactic body radiation therapy or SBRT as a possible treatment for Cancer that has spread to the spine or other bone
Conditions Studied
Interventions
- DRUG Stereotactic Body Radiation Therapy (SBRT)
- DEVICE Stereotactic Linear Accelerator
Study Locations (1)
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2016-11-29 |
| Est. Completion | 2027-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02880319
The ClinicalTrials.gov registry entry for NCT02880319 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 686-participant average among 3 other Bone Cancer trials with a reported enrollment target (78% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bone Cancer appearing as the primary indexed condition, and to 2 interventions - of which Stereotactic Body Radiation Therapy (SBRT) is the first listed.
NCT02880319 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02880319 about?
NCT02880319 is a clinical study titled "Evaluating Stereotactic Body Radiation Therapy for Oligometastatic Disease of the Bone". This research study is studying a form of radiation therapy called stereotactic body radiation therapy or SBRT as a possible treatment for Cancer that has spread to the spine or other bone
What is the current status of trial NCT02880319?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2016-11-29. Estimated completion is 2027-05.
What conditions does trial NCT02880319 study?
This clinical trial studies the following conditions: Bone Cancer.
What interventions are being tested in trial NCT02880319?
The interventions under investigation include: Stereotactic Body Radiation Therapy (SBRT) (DRUG), Stereotactic Linear Accelerator (DEVICE).
Who is sponsoring clinical trial NCT02880319?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02880319 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bone Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Osteosarcoma Maintenance Therapy With OST31-164
ACTIVE NOT RECRUITING · Phase 2
-
Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
COMPLETED · Phase 2
-
Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
RECRUITING
-
Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.